Other News To Note
Wednesday, July 18, 2012
BioTime Inc., of Alameda, Calif., signed an exclusive sublicense agreement and a supply agreement with Jade Therapeutics LLC, of Park City, Utah, to provide clinical-grade HyStem hydrogels and other technology for use by Jade in developing pharmaceutical products for ophthalmologic use. Jade plans to use the hydrogels for time-release topical delivery of recombinant human growth hormone to help heal lesions on the ocular surface.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.